GST-HG131

Phase 2Small molecule

FFujian Akeylink Biotechnology Co., Ltd.

GST-HG131 is one of 26 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 3

Incivek

Vertex Pharmaceuticals

Preclinical

10 4

Intron a

Sanofi

Preclinical

7 5

Roferon-a

Roche

Preclinical

3 6

Medrol

Pfizer

Preclinical

1 7

Dasabuvir

AbbVie

Preclinical

7 8

SOF/VEL

Gilead

Preclinical

4 9

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

1 10

Pegintron

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tics1 trial

Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of GST-HG131 Tablets

Unknown status·FFujian Cosunter Pharmaceutical Co. Ltd·Phase 1·NCT04499443·124 enrolled

Chronic Hepatitis1 trial

A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B

Recruiting·FFujian Akeylink Biotechnology Co., Ltd.·Phase 2·NCT06263959·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for GST-HG131. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GST-HG131 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GST-HG131. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fujian Akeylink Biotechnology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFujian Akeylink Biotechnology Co., Ltd.

GST-HG131

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tics1 trial

Chronic Hepatitis1 trial

References

Drug Info

Quick Facts

Related News